Patents by Inventor Keiko Yoshimoto
Keiko Yoshimoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210393634Abstract: The present invention provides a prophylactic and/or therapeutic agent for inflammatory disease including a compound or a salt thereof, or a solvate thereof, the compound represented by a formula (1): [where each sign is defined as described in the description] as an active ingredient.Type: ApplicationFiled: May 10, 2019Publication date: December 23, 2021Applicant: KEIO UNIVERSITYInventors: Tsutomu Takeuchi, Katsuya Suzuki, Keiko Yoshimoto
-
Publication number: 20210215705Abstract: An antibody against a peptide having an amino acid sequence AVQGPEETVT QDC (expressed in single letter amino acid code) as represented by SEQ ID: NO. 1 corresponding to the 134- to 146-positions in human BAFF (B cell activating factor belonging to the TNF family) protein which is preferably a monoclonal antibody; a method of producing the above antibody; a medicinal composition containing the antibody; utilization of the antibody; and a method of screening an inhibitory effect or an activating effect on BAFF with the use of the antibody.Type: ApplicationFiled: March 26, 2021Publication date: July 15, 2021Applicants: KOWA COMPANY, LTD.Inventors: Tsutomu Takeuchi, Keiko Yoshimoto
-
Publication number: 20140024055Abstract: An antibody against a peptide having an amino acid sequence AVQGPEETVT QDC (expressed in single letter amino acid code) as represented by SEQ ID: NO. 1 corresponding to the 134- to 146-positions in human BAFF (B cell activating factor belonging to the TNF family) protein which is preferably a monoclonal antibody; a method of producing the above antibody; a medicinal composition containing the antibody; utilization of the antibody; and a method of screening an inhibitory effect or an activating effect on BAFF with the use of the antibody.Type: ApplicationFiled: October 3, 2013Publication date: January 23, 2014Applicants: KOWA COMPANY, LTD.Inventors: Tsutomu Takeuchi, Keiko Yoshimoto
-
Patent number: 8017329Abstract: A method of screening a novel BAFF suppressor or inhibitor. More specifically speaking, a method which comprises adding a combination of TPA with ionomycin and/or an anti-CD3 antibody to a cultured human cell to thereby induce the production of BAFF by the cell; a method of screening a substance capable of suppressing the expression or activity of BAFF which comprises adding a test substance to a BAFF-production system prepared by adding a combination of TPA with ionomycin and/or an anti-CD3 antibody to a cultured human cell and measuring the expression amount and/or the activity of BAFF in the BAFF-production system; and a BAFF production inducer for a BAFF-producing cell which contains a combination of TPA with ionomycin and/or an anti-CD3 antibody.Type: GrantFiled: March 31, 2010Date of Patent: September 13, 2011Assignees: Kowa Company, Ltd.Inventors: Tsutomu Takeuchi, Kensei Tsuzaka, Keiko Yoshimoto
-
Publication number: 20110081351Abstract: An antibody against a peptide having an amino acid sequence AVQGPEETVT QDC (expressed in single letter amino acid code) as represented by SEQ ID: NO. 1 corresponding to the 134- to 146-positions in human BAFF (B cell activating factor belonging to the TNF family) protein which is preferably a monoclonal antibody; a method of producing the above antibody; a medicinal composition containing the antibody; utilization of the antibody; and a method of screening an inhibitory effect or an activating effect on BAFF with the use of the antibody.Type: ApplicationFiled: September 27, 2010Publication date: April 7, 2011Applicants: KOWA COMPANY, LTD.Inventors: Tsutomu Takeuchi, Keiko Yoshimoto
-
Patent number: 7846662Abstract: A method of screening a novel BAFF suppressor or inhibitor. More specifically speaking, a method which comprises adding a combination of TPA with ionomycin and/or an anti-CD3 antibody to a cultured human cell to thereby induce the production of BAFF by the cell; a method of screening a substance capable of suppressing the expression or activity of BAFF which comprises adding a test substance to a BAFF-production system prepared by adding a combination of TPA with ionomycin and/or an anti-CD3 antibody to a cultured human cell and measuring the expression amount and/or the activity of BAFF in the BAFF-production system; and a BAFF production inducer for a BAFF-producing cell which contains a combination of TPA with ionomycin and/or an anti-CD3 antibody.Type: GrantFiled: September 14, 2005Date of Patent: December 7, 2010Assignees: Kowa Company, Ltd.Inventors: Tsutomu Takeuchi, Kensei Tsuzuka, Keiko Yoshimoto
-
Publication number: 20100196948Abstract: A method of screening a novel BAFF suppressor or inhibitor. More specifically speaking, a method which comprises adding a combination of TPA with ionomycin and/or an anti-CD3 antibody to a cultured human cell to thereby induce the production of BAFF by the cell; a method of screening a substance capable of suppressing the expression or activity of BAFF which comprises adding a test substance to a BAFF-production system prepared by adding a combination of TPA with ionomycin and/or an anti-CD3 antibody to a cultured human cell and measuring the expression amount and/or the activity of BAFF in the BAFF-production system; and a BAFF production inducer for a BAFF-producing cell which contains a combination of TPA with ionomycin and/or an anti-CD3 antibody.Type: ApplicationFiled: March 31, 2010Publication date: August 5, 2010Applicants: KOWA COMPANY, LTD.Inventors: Tsutomu Takeuchi, Kensei Tsuzaka, Keiko Yoshimoto
-
Publication number: 20080305502Abstract: A method of screening a novel BAFF suppressor or inhibitor. More specifically speaking, a method which comprises adding a combination of TPA with ionomycin and/or an anti-CD3 antibody to a cultured human cell to thereby induce the production of BAFF by the cell; a method of screening a substance capable of suppressing the expression or activity of BAFF which comprises adding a test substance to a BAFF-production system prepared by adding a combination of TPA with ionomycin and/or an anti-CD3 antibody to a cultured human cell and measuring the expression amount and/or the activity of BAFF in the BAFF-production system; and a BAFF production inducer for a BAFF-producing cell which contains a combination of TPA with ionomycin and/or an anti-CD3 antibody.Type: ApplicationFiled: September 14, 2005Publication date: December 11, 2008Applicant: Kowa Company, LTD.Inventors: Tsutomu Takeuchi, Kensei Tsuzaka, Keiko Yoshimoto
-
Publication number: 20080050381Abstract: An antibody against a peptide having an amino acid sequence AVQGPEETVT QDC (expressed in single letter amino acid code) corresponding to the 134- to 146-positions in human BAFF (B cell activating factor belonging to the TNF family) protein which is preferably a monoclonal antibody; a method of producing the above antibody; a medicinal composition containing the antibody; utilization of the antibody; and a method of screening an inhibitory effect or an activating effect on BAFF with the use of the antibody.Type: ApplicationFiled: August 30, 2005Publication date: February 28, 2008Applicants: KOWA COMPANY, LTD.Inventors: Tsutomu Takeuchi, Keiko Yoshimoto